Post

Biology is dizzyingly complex, and yet almost every medicine humanity has ever made acts on a single target in the body. Just a handful can interact with two distinct targets, and these are some of the most exciting treatments to enter the clinic in the past decade.

To truly control biology, we need medicines that can engage multiple targets simultaneously, but traditional modalities like small molecules and antibodies struggle to do this.

In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.

This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.